Inhibitor Therapeutics, Inc. (OTC:INTI)
| Market Cap | $13.90M+60.0% |
| Revenue (ttm) | $0 |
| Net Income | -$3.19M+7.0% |
| EPS | -$0.02+7.5% |
| Shares Out | 173.79M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 80,000 |
| Open | $0.08 |
| Previous Close | $0.08 |
| Day's Range | $0.08 - $0.08 |
| 52-Week Range | $0.04 - $0.12 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | n/a |
About INTI
Inhibitor Therapeutics, Inc., established in 1992 and based in Tampa, Florida, is a pharmaceutical development enterprise. The company is dedicated to inventing and commercializing medical treatments for patients in the United States who suffer from various cancerous and non-cancerous cell proliferation conditions. A primary focus of their work involves advancing SUBA-Itraconazole, an oral variant of the drug itraconazole, for therapeutic applications in prostate and lung cancers. Furthermore, Inhibitor Therapeutics, Inc. has successfully completed a positive Phase 2b clinical trial for SUBA-Itraconazole in the management of basal cell carcinoma nevus syndrome. The organization was previously known as HedgePath Pharmaceuticals, Inc. until its name was officially changed in August 2019.
$INTI stock is featured in our Insider Trades datasets.
→ All Stock ListsRecently reported changes in INTI holdings by institutional investors
Latest 0 13F filings · Source: SEC EDGAR
View all institutional owners →Insider Trading
Quarterly net insider trading by INTI's directors and management
Source: SEC EDGAR (Form 4)
Corporate Lobbying
INTI Estimated quarterly lobbying spending
Source: U.S. Senate LDA
U.S. Patents
New INTI patent grants
Source: USPTO Open Data Portal
Government Contracts
Estimated quarterly amount awarded to INTI from public contracts
Source: USAspending.gov
Bull Case vs Bear Case
AI-generated from INTI’s recent data — informational, not investment advice
